399 related articles for article (PubMed ID: 19549186)
1. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety.
Brandt F; Swanson N; Baumann L; Huber B
Dermatol Surg; 2009 Dec; 35(12):1893-901. PubMed ID: 19549186
[TBL] [Abstract][Full Text] [Related]
2. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
Baumann L; Brandt FS; Kane MA; Donofrio LM
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S57-65. PubMed ID: 19945006
[TBL] [Abstract][Full Text] [Related]
3. A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint.
Hanke CW; Narins RS; Brandt F; Cohen JL; Donofrio LM; Downie J; Heinz M; Harrington L; McDaniel DH; Nestor M; Schlessinger J; Schlöbe A; Taub A; Weiss RA
Dermatol Surg; 2013 Jun; 39(6):891-9. PubMed ID: 23506308
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study.
Wu Y; Fang F; Lai W; Li C; Li L; Liu Q; Lu J; Pang X; Sun J; Shi X; Picaut P; Prygova I; Andriopoulos B; Sun Q
Aesthetic Plast Surg; 2023 Feb; 47(1):351-364. PubMed ID: 36536093
[TBL] [Abstract][Full Text] [Related]
5. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines.
Carruthers JD; Lowe NJ; Menter MA; Gibson J; Eadie N;
Plast Reconstr Surg; 2003 Sep; 112(4):1089-98. PubMed ID: 12973229
[TBL] [Abstract][Full Text] [Related]
6. Correlation of botulinum toxin dose with neurophysiological parameters of efficacy and safety in the glabellar muscles: a double-blind, placebo-controlled, randomized study.
Alimohammadi M; Andersson M; Punga AR
Acta Derm Venereol; 2014 Jan; 94(1):32-7. PubMed ID: 23975053
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment.
Rubin MG; Dover J; Glogau RG; Goldberg DJ; Goldman MP; Schlessinger J
J Drugs Dermatol; 2009 May; 8(5):439-44. PubMed ID: 19537366
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results From 2 Identical Phase III Studies.
Beer KR; Shamban AT; Avelar RL; Gross JE; Jonker A
Dermatol Surg; 2019 Nov; 45(11):1381-1393. PubMed ID: 30893162
[TBL] [Abstract][Full Text] [Related]
9. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
Carruthers A; Carruthers J; Coleman WP; Donofrio L; Flynn T; Gold M; Heinz M; Harrington L; Jones D; McDaniel D; Rohrer T; Schlöbe A; Solish N; Weiss RA
Dermatol Surg; 2013 Apr; 39(4):551-8. PubMed ID: 23379292
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines.
Kim JE; Song EJ; Choi GS; Lew BL; Sim WY; Kang H
Plast Reconstr Surg; 2015 Mar; 135(3):732-741. PubMed ID: 25719692
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Botulinum Toxin Type A for Treatment of Glabellar Lines: A Network Meta-Analysis of Randomized Controlled Trials.
Li X; Sui C; Xia X; Chen X
Aesthetic Plast Surg; 2023 Feb; 47(1):365-377. PubMed ID: 36097079
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines.
Carruthers JA; Lowe NJ; Menter MA; Gibson J; Nordquist M; Mordaunt J; Walker P; Eadie N;
J Am Acad Dermatol; 2002 Jun; 46(6):840-9. PubMed ID: 12063480
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study.
Kane MAC; Brandt F; Rohrich RJ; Narins RS; Monheit GD; Huber MB;
Plast Reconstr Surg; 2009 Nov; 124(5):1619-1629. PubMed ID: 19584772
[TBL] [Abstract][Full Text] [Related]
14. Time to onset of response of abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type A.
Schlessinger J; Monheit G; Kane MA; Mendelsohn N
Dermatol Surg; 2011 Oct; 37(10):1434-42. PubMed ID: 21745254
[TBL] [Abstract][Full Text] [Related]
15. A Phase III Clinical Study of the Efficacy and Safety of Botulinum Toxin Type A (MASPORT) with DYSPORT for the Treatment of Glabellar Lines.
Hedayat K; Ehsani AH
Aesthetic Plast Surg; 2024 Feb; 48(3):324-332. PubMed ID: 38233684
[TBL] [Abstract][Full Text] [Related]
16. A four-month randomized, double-blind evaluation of the efficacy of botulinum toxin type A for the treatment of glabellar lines in women with skin types V and VI.
Grimes PE; Shabazz D
Dermatol Surg; 2009 Mar; 35(3):429-35; discussion 435-6. PubMed ID: 19250310
[TBL] [Abstract][Full Text] [Related]
17. DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2).
Carruthers JD; Fagien S; Joseph JH; Humphrey SD; Biesman BS; Gallagher CJ; Liu Y; Rubio RG; ;
Plast Reconstr Surg; 2020 Jan; 145(1):45-58. PubMed ID: 31609882
[TBL] [Abstract][Full Text] [Related]
18. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
Rzany BJ; Ascher B; Avelar RL; Bergdahl J; Bertucci V; Bodokh I; Carruthers JA; Cartier H; Delmar H; Denfeld R; Gross JE; Heckmann M; Hedén P; Hilton S; Inglefield C; Ogilvie P; Sattler G; Sebastian M; Solish N; Swift A; Trévidic P
Aesthet Surg J; 2020 Mar; 40(4):413-429. PubMed ID: 30951166
[TBL] [Abstract][Full Text] [Related]
19. An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
Rubin M; Dover J; Maas C; Nestor M
Aesthet Surg J; 2009 Nov; 29(6 Suppl):S50-6. PubMed ID: 19945005
[TBL] [Abstract][Full Text] [Related]
20. OnabotulinumtoxinA treatment of mild glabellar lines in repose.
Carruthers A; Carruthers J; Lei X; Pogoda JM; Eadie N; Brin MF
Dermatol Surg; 2010 Dec; 36 Suppl 4():2168-71. PubMed ID: 21134048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
